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INTRODUCTION  
Methods and software tools for optimal design in nonlinear mixed effect models (NLMEM) 
have been developed and proposed for a decade1. They are based on the evaluation and 
optimisation of the Fisher information matrix, whose inverse is a lower bound of the 
expected variance of estimation. Since the first optimal design tools for population 
pharmacokinetics2, at least 5 software tools have been developed and new versions3-5 
with improvements have been made available on a regular basis by several academic 
groups. They are mainly applied for pharmacokinetic-pharmacodynamic (PKPD) studies. 
Present tools do not yet allow optimization of adaptive designs for these models, 
although prior information on models and parameter values are needed and adaptive 
designs are increasingly used and promising in drug development6,.  Before developing 
this capacity we conducted a study among the 10 drug companies which are members of 
the Drug Disease Model Resources (DDMoRe) European consortium7 to identify current 
practices, shortcomings and expectations. 
 
STUDY ON USE OF OPTIMAL DESIGN IN PHARMACOMETRICS 
In 2011, the Drug Disease Model Resources (DDMoRe) consortium was approved as one 
of the Innovative Medicines Initiative (IMI) projects of the European Union with the 
objective of developing a drug-disease model library and an open-source interoperability 
framework7. This project associates 9 academic groups, 6 small and medium sized 
enterprises, and 10 pharmaceutical companies that are members of the European 
Federation of Pharmaceutical  Industries and Associations (EFPIA). One of the work 
packages within DDMoRe is responsible for development and integration of new tools, 
among others also for adaptive optimal designs in PKPD using nonlinear mixed effect 
models (NLMEM).  
The working group members and authors of this article designed a questionnaire for this 
study. It was sent to each EFPIA representative within DDMoRE in October 2011. Each 
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representative was then in charge to ask one to three scientists within the company to 
respond to the questionnaire, mostly to those indeed involved in designing PKPD studies. 
The detailed questionnaire is available as Supplementary Figure S1. Responders first 
stated how clinical trials were generally designed, by simulations, heuristic approaches 
and/or optimal design. The main body of the survey was composed of two parts, part 1: 
state of the art on the use of optimal design methods in industry, part 2:  requests for 
future developments using adaptive optimal design.  
 
RESULTS  
Results were obtained in November 2011 from all the 10 member companies of the 
DDMoRe consortium (100% response rate): AstraZeneca, GSK, Lilly, Merck Serono, 
Novartis, Novo Nordisk, Pfizer, Roche, Servier, UCB Pharma.  
Current Situation 
Part 1 of the study investigated the current situation. The first question showed that 
optimal design software tools in NLMEM are being used by nearly all companies (9/10), 
mostly during Phase 1 and 2 for Pharmacokinetics (PK)/Pharmacodynamics (PD), 
sometimes for biopharmaceutical studies later in development in special populations:  
paediatric patients, patients with renal or hepatic impairment and the elderly. All 
currently available software tools were used among the respondents. Here a list of the 
programs and their frequency of usage: PFIM (University Paris Diderot & INSERM, 6/9), 
POPED (University of Uppsala, 3/9), POPDES (University of Manchester, 3/9), POPT 
(University of Otago, 3/9).  
Optimal design approaches are used for a variety of investigations and design complexity 
(Table 1). Interestingly, optimal design is often used in early clinical phases (I and II), 
and less in phase III; one responder suggested that there is a lack of models able to 
handle complex endpoints encountered in later phases. Current limitations were 
expressed in free text which is available as Supplementary Table S1. The most common 
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limitation was the need to change software when moving from estimation to design, 
showing a strong need for more integrative/global approaches/tools. Several companies 
were concerned about the limited models currently implemented in most optimal design 
software tools and suggested to add more flexibility. Overall, the perceived impact of 
optimal design was generally considered quite important, with potentially wider 
applications suggested in the industry. 
Adaptive Designs and further developments 
Adaptive design in NLMEM is of high priority for most companies with a median of 4, on 
a scale of 0 to 5, with 4 companies quoting a 5 (very useful). The answers to specific 
needs were: (i) start from prior information (8/9), (ii) design optimisation after each new 
cohort (8/9), (iii) use stopping rules (6/9). One company highlighted that adaptive 
design is not possible in therapeutic areas where endpoints are attained slowly while 
recruitment is fast. 
The importance of new developments in design tools was graded on a scale from 0 to 5. 
Results are given in Table 2 and show that the priorities are: (i) handling of continuous 
covariates, (ii) dealing with data below quantification limit, (iii) robustness across 
models, and (iv) design for discrete outcome data also in combination with continuous 
data. Additional expectations were expressed in text (Supplementary Table S1). 
 
CONCLUSION  
This study illustrates that optimal design methodology has been quickly adopted within 
the industry, especially in early phases where PKPD is more important. This is study 
further highlights expected improvements in interoperability between optimal design and 
estimation software and in statistical capabilities of the optimal design methodology. A 
smooth workflow between estimation, model evaluation and design will be facilitated on 
the DDMoRe platform. It should be noted that we did not perform a comprehensive 
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systematic review of the use of optimal design software tool in NLMEM in drug 
companies outside of DDMoRe, therefore the presented results may be biased. 
Another outcome of the study is the high priority was given to further development of 
adaptive optimal design (AOD) in NLMEM with optimisation not only of sampling times 
but of other design variables, e.g. doses (Table 1). Initial work on AOD in population PK 
demonstrated its feasibility8, but the approach is not yet fully studied nor implemented 
in any available software. Those developments will only address some of the issues of 
the complexity of adaptive design in drug development. For instance, adaptive dose-
ranging studies analysed by nonlinear models without random effects, are already being 
optimised6. Also, as pharmacometrics has increased its scope beyond population PK, 
design tools for more complex models and for other types of data, especially discrete 
data, are now needed. Academic groups are actively working on those topics and are 
sharing their results to translate progress into new software tools, but collaborations 
with statisticians involved in other aspects of the complex issues in adaptive designs are 
also increasingly needed. Optimal design enriches clinical trial simulation, and both will 
work in concert to improve model-based drug development in the pharmaceutical 
industry. 
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Table 1: Current use of optimal design software tools for the n=9 EFPIA 
companies, out of the 10 of DDMoRe, presently using this approach. 
 
 Yes 
Type of investigations  
Design evaluation 7 
Design optimisation 8 
Power evaluation 6 
Complexity of designs  
Dose/input optimisation 6 
Sampling windows in designs 7 
Several group of elementary designs  7 
Bayesian/robust approaches 5 
Complex error models 3 
Inter-occasion variability  3 
Covariates  5 
Multi-response models 4 
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Table 2: Expectations of n=10 EFPIA companies of DDMoRe regarding 
capabilities of a new optimal design software  
 Median Range 
Accepts continuous covariates 5 3-5 
Handles data below quantification limit 4 2-5 
Handles robustness across models 4 2-5 
Handles discrete data 4 1-5 
Handles jointly continuous and discrete data 4 1-5 
Handles repeated time to event (rtte) data  3 1-5 
Predicts shrinkage 3 1-5 
Provides standard errors for individual parameters 3 1-5 
Provides choice of several  optimality criteria  3 1-5 
Handles jointly continuous and rtte data  3 1-3 
Scale from 0 to 5. 
 
